Chimerix   Report issue

For profit Phase 1 Phase 3
Founded: Durham NC United States (2002)

Organization Overview

First Clinical Trial
2008
NCT00780182
First Marketed Drug
2021
brincidofovir
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Chimerix | CHIMERIX

Active Ingredients

Marketed Drugs (1)

brincidofovir (2021)

Drugs in Phase 3 Trials (5)

Key: Chimerix (4) Acquired (1)

brincidofovir (17 trials)

dociparstat sodium (2 trials)

everolimus (zortress) (1 trial)

onc201 (16 trials)

valganciclovir (valcyte) (2 trials)

Drugs in Phase 1 Trials (4)

Key: Chimerix (2) Acquired (2)

atezolizumab (tecentriq) (1 trial)

cmx 157 (1 trial)

onc206 (2 trials)

tenofovir (viread) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Adenoviridae Infections (Phase 3)

Communicable Diseases (Phase 3)

Cytomegalovirus Infections (Phase 3)

Disease (Phase 3)

Hemorrhagic Fever, Ebola (Phase 2)

Infections (Phase 3)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lung Injury (Phase 3)

Monkeypox (Phase 3)

Respiratory Distress Syndrome (Phase 3)

Respiratory Insufficiency (Phase 3)

Viremia (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 38
  • # of Trial APIs: 9